Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [14C]-LY3372689 in Healthy Males
NCT05749848Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceperognastat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3372689 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and Fecal Excretion of LY3372689 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Feb 2023; status: completed.
02
Drugs
ceperognastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05749848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749848.